198 related articles for article (PubMed ID: 38180692)
1. Stage 3 N2 Lung Cancer: A Multidisciplinary Therapeutic Conundrum.
Carter L; Apte V; Shukla A; Ghose A; Mamidi R; Petohazi A; Makker S; Banerjee S; Boussios S; Banna GL
Curr Oncol Rep; 2024 Jan; 26(1):65-79. PubMed ID: 38180692
[TBL] [Abstract][Full Text] [Related]
2. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
3. Role of surgery in N2 NSCLC: pros.
Shien K; Toyooka S
Jpn J Clin Oncol; 2016 Dec; 46(12):1168-1173. PubMed ID: 27655902
[TBL] [Abstract][Full Text] [Related]
4. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
Xu YP; Li B; Xu XL; Mao WM
Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.
Yang RX; Hei Y; Zhu WT; Wang QR; Zhang HM; Chen Y
Curr Oncol; 2022 Aug; 29(9):6203-6210. PubMed ID: 36135056
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial).
Kocher F; Pircher A; Mohn-Staudner A; Romeder F; Duller W; Steinmaurer M; Eckmayr J; Schmid T; Hilbe W; Fiegl M; Greil R
Lung Cancer; 2014 Sep; 85(3):395-400. PubMed ID: 25043642
[TBL] [Abstract][Full Text] [Related]
7. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
8. Management of Resectable Stage III-N2 Non-Small-Cell Lung Cancer (NSCLC) in the Age of Immunotherapy.
Mielgo-Rubio X; Montemuiño S; Jiménez U; Luna J; Cardeña A; Mezquita L; Martín M; Couñago F
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638296
[TBL] [Abstract][Full Text] [Related]
9. [Review on Treatment Modalities for Resectable IIIa/N2 Non-small Cell Lung Cancer].
Xu Z; Xing P; Ma D; Zhu Y; Ying J; Li J
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):111-117. PubMed ID: 30827328
[TBL] [Abstract][Full Text] [Related]
10. Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer.
Tanaka F; Yokomise H; Soejima T; Uramoto H; Yamanaka T; Nakagawa K; Yamamoto N; Nishimura Y; Niwa H; Okada M; Nakagawa T; Yamashita M
Ann Thorac Surg; 2018 Oct; 106(4):1018-1024. PubMed ID: 29890150
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant treatment followed by surgery versus definitive chemoradiation in stage IIIA-N2 non-small-cell lung cancer: A multi-institutional study by the oncologic group for the study of lung cancer (Spanish Radiation Oncology Society).
Couñago F; Rodriguez de Dios N; Montemuiño S; Jové-Teixidó J; Martin M; Calvo-Crespo P; López-Mata M; Samper-Ots MP; López-Guerra JL; García-Cañibano T; Díaz-Díaz V; de Ingunza-Barón L; Murcia-Mejía M; Alcántara P; Corona J; Puertas MM; Chust M; Couselo ML; Del Cerro E; Moradiellos J; Amor S; Varela A; Thuissard IJ; Sanz-Rosa D; Taboada B
Lung Cancer; 2018 Apr; 118():119-127. PubMed ID: 29571989
[TBL] [Abstract][Full Text] [Related]
12. Importance of tumor size in resectable stage III-N2 non-small cell lung cancer.
Castro PP; de Perrot M; Chua YC; Bezjak A; Leighl N; Darling G; Pierre A; Yasufuku K; Cypel M; Waddell T; Donahoe L; Yeung J; Keshavjee S
J Thorac Cardiovasc Surg; 2022 Sep; 164(3):629-636. PubMed ID: 35331553
[TBL] [Abstract][Full Text] [Related]
13. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Ramnath N; Dilling TJ; Harris LJ; Kim AW; Michaud GC; Balekian AA; Diekemper R; Detterbeck FC; Arenberg DA
Chest; 2013 May; 143(5 Suppl):e314S-e340S. PubMed ID: 23649445
[TBL] [Abstract][Full Text] [Related]
14. Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
Mainguene J; Basse C; Girard P; Beaucaire-Danel S; Cao K; Brian E; Grigoroiu M; Gossot D; Luporsi M; Perrot L; Vieira T; Caliandro R; Daniel C; Seguin-Givelet A; Girard N
Lung Cancer; 2022 Jan; 163():51-58. PubMed ID: 34922144
[TBL] [Abstract][Full Text] [Related]
15. Advances in the use of surgery and multimodality treatment for N2 non-small cell lung cancer.
Van Schil PE; Yogeswaran K; Hendriks JM; Lauwers P; Faivre-Finn C
Expert Rev Anticancer Ther; 2017 Jun; 17(6):555-561. PubMed ID: 28403675
[TBL] [Abstract][Full Text] [Related]
16. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
Pless M; Stupp R; Ris HB; Stahel RA; Weder W; Thierstein S; Gerard MA; Xyrafas A; Früh M; Cathomas R; Zippelius A; Roth A; Bijelovic M; Ochsenbein A; Meier UR; Mamot C; Rauch D; Gautschi O; Betticher DC; Mirimanoff RO; Peters S;
Lancet; 2015 Sep; 386(9998):1049-56. PubMed ID: 26275735
[TBL] [Abstract][Full Text] [Related]
17. Results of trimodality therapy in patients with stage IIIA (N2-bulky) and stage IIIB non-small-cell lung cancer.
Li J; Dai CH; Yu LC; Chen P; Li XQ; Shi SB; Wu JR
Clin Lung Cancer; 2009 Sep; 10(5):353-9. PubMed ID: 19808194
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
Mirimanoff RO
Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
[TBL] [Abstract][Full Text] [Related]
19. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy.
Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R
Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715
[TBL] [Abstract][Full Text] [Related]
20. Reaching multidisciplinary consensus on the management of non-bulky/non-infiltrative stage IIIA N2 non-small cell lung cancer.
Scherpereel A; Martin E; Brouchet L; Corre R; Duruisseaux M; Falcoz PE; Giraud P; Le Péchoux C; Wislez M; Alifano M
Lung Cancer; 2023 Mar; 177():21-28. PubMed ID: 36682142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
